Ep196: Otello Stampacchia on Europe's Biotech Crisis

European biotech's competitive position in the global landscape is at risk due to geopolitical pressures and financial constraints. Otello Stampacchia of Omega Funds discusses Europe's need to mobilize public and private capital to support its biotech industry, which currently receives only 7% of global venture capital. A key issue is the fragmentation of European capital markets, leading many biotech companies to list on non-EU exchanges, primarily in the U.S. Europe's slow and fragmented regulatory framework for clinical trials also puts it at a disadvantage compared to countries like China and Australia. The European Life Sciences Coalition is advocating for policy changes to address these market failures and foster a more supportive environment for biotech innovation.